Latigo Biotherapeutics appoints Neha Krishnamohan as CFO and CBO

Lucy Batizovsky | March 10, 2026 | Appointment | |  Latigo Biotherapeutics 

Latigo Biotherapeutics, a clinical-stage biopharmaceutical company developing non-opioid pain medicines, announced the appointment of Neha Krishnamohan as Chief Financial Officer (CFO) and Chief Business Officer (CBO).

Neha has more than 15 years of experience in healthcare investment banking, corporate finance and strategic leadership in the biopharmaceutical, medical technology, and tools and diagnostics sectors. Most recently, she served as CFO and Executive Vice President (EVP) of corporate development at Artiva Biotherapeutics.

Nima Farzan, chief executive officer of Latigo, said: “Neha’s financial stewardship, strategic insight and experience across corporate strategy, business development, capital markets and leading companies through high-impact corporate milestones will be critical as we progress our clinical programmes and build long-term shareholder value.”

Advertisement

Until recently, Neha was the audit committee chair on Latigo’s board of directors and is currently on the board of Arcutis Biotherapeutics, serving as a member of the audit committee.

Neha said: “Latigo has the potential to transform pain management with a differentiated pipeline of non-opioid pain programmes. I look forward to partnering with Latigo’s talented management team and board to advance Latigo’s strategic and financial objectives.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content